mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2

[1]  Mark M. Davis,et al.  Durability of immune responses to the BNT162b2 mRNA vaccine. , 2022, Med.

[2]  Manish M Patel,et al.  Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines , 2021, Nature Communications.

[3]  Larissa B. Thackray,et al.  Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains , 2021, Science Translational Medicine.

[4]  Vineet D. Menachery,et al.  The N501Y spike substitution enhances SARS-CoV-2 infection and transmission , 2021, Nature.

[5]  Jessica K. Fiege,et al.  Mice with diverse microbial exposure histories as a model for preclinical vaccine testing. , 2021, Cell host & microbe.

[6]  M. Mulligan,et al.  Neutralization of Mu and C.1.2 SARS-CoV-2 Variants by Vaccine-elicited Antibodies in Individuals With and Without Previous History of Infection , 2021 .

[7]  F. Fratev.  The R346K Mutation in the Mu Variant of SARS-CoV-2 Alter the Interactions with Monoclonal Antibodies from Class 2: A Free Energy of Perturbation Study , 2021, bioRxiv.

[8]  B. Pulendran,et al.  Durability of immune responses to the BNT162b2 mRNA vaccine , 2021 .

[9]  A. Ryo,et al.  Neutralizing efficacy of vaccines against the SARS-CoV-2 Mu variant , 2021, medRxiv.

[10]  M. Nussenzweig,et al.  High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape , 2021, Nature.

[11]  K. Natarajan,et al.  Interim Estimates of COVID-19 Vaccine Effectiveness Against COVID-19–Associated Emergency Department or Urgent Care Clinic Encounters and Hospitalizations Among Adults During SARS-CoV-2 B.1.617.2 (Delta) Variant Predominance — Nine States, June–August 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[12]  Anthony Z. Matolek,et al.  Effectiveness of COVID-19 mRNA Vaccines Against COVID-19–Associated Hospitalization — Five Veterans Affairs Medical Centers, United States, February 1–August 6, 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[13]  J. Bloom,et al.  Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters , 2021, mBio.

[14]  A. Kaneda,et al.  Ineffective neutralization of the SARS-CoV-2 Mu variant by convalescent and vaccine sera , 2021, bioRxiv.

[15]  A. Fowlkes,et al.  Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance — Eight U.S. Locations, December 2020–August 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[16]  David W. McDonald,et al.  Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults — United States, March–July 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[17]  R. Link-Gelles,et al.  Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant — National Healthcare Safety Network, March 1–August 1, 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[18]  D. Lauffenburger,et al.  Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination , 2021, Cell Reports Medicine.

[19]  D. Fremont,et al.  A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope , 2021, Immunity.

[20]  Thomas P. Fabrizio,et al.  A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants , 2021, Immunity.

[21]  M. Ciccozzi,et al.  A cluster of the new SARS‐CoV‐2 B.1.621 lineage in Italy and sensitivity of the viral isolate to the BNT162b2 vaccine , 2021, Journal of medical virology.

[22]  D. Fremont,et al.  A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters , 2021, Cell Reports.

[23]  R. Andino,et al.  In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. , 2021, Nature.

[24]  H. Schuitemaker,et al.  Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans , 2021, Nature.

[25]  Gerardo del Cerro Santamaría,et al.  Characterization of the emerging B.1.621 variant of interest of SARS-CoV-2 , 2021, Infection, Genetics and Evolution.

[26]  R. Andino,et al.  In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains , 2021, Nature.

[27]  Ahmed Abdul Azim,et al.  Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19. , 2021, JAMA.

[28]  D. Fremont,et al.  Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies , 2021, Nature Medicine.

[29]  M. Nussenzweig,et al.  mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants , 2021, Nature.

[30]  Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization , 2021, Cell Host & Microbe.

[31]  A. García-Sastre,et al.  The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice and is neutralized by convalescent and post-vaccination human sera , 2021, medRxiv.

[32]  M. Nussenzweig,et al.  mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants , 2021, bioRxiv.

[33]  H. Schuitemaker,et al.  Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine , 2021, The New England journal of medicine.

[34]  Jianping Wu,et al.  Functional and genetic analysis of viral receptor ACE2 orthologs reveals a broad potential host range of SARS-CoV-2 , 2020, Proceedings of the National Academy of Sciences.

[35]  D. Fremont,et al.  A single intranasal or intramuscular immunization with chimpanzee adenovirus vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters , 2020, bioRxiv.

[36]  Vineet D. Menachery,et al.  Spike mutation D614G alters SARS-CoV-2 fitness , 2020, Nature.

[37]  H. Schuitemaker,et al.  Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses , 2020, NPJ vaccines.

[38]  D. Lauffenburger,et al.  Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality , 2020, Cell.

[39]  Shamus P. Keeler,et al.  SARS-CoV-2 infection of hACE2 transgenic mice causes severe lung inflammation and impaired function , 2020, Nature Immunology.

[40]  H. Schuitemaker,et al.  Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses , 2020, npj Vaccines.

[41]  Yan Li,et al.  Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy , 2020, Science.

[42]  Larissa B. Thackray,et al.  A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies , 2020, Cell.

[43]  Shrutika Mintri,et al.  Impact of mRNA chemistry and manufacturing process on innate immune activation , 2020, Science Advances.

[44]  C. Cunningham-Rundles,et al.  A serological assay to detect SARS-CoV-2 seroconversion in humans , 2020, Nature Medicine.

[45]  H. Yen,et al.  Peer Review File Manuscript Title: Pathogenesis and transmission of SARS-CoV-2 in golden Syrian hamsters , 2020 .

[46]  M. Diamond,et al.  TMPRSS2 and TMPRSS4 mediate SARS-CoV-2 infection of human small intestinal enterocytes , 2020, bioRxiv.

[47]  Kaijun Jiang,et al.  SARS‐CoV‐2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup , 2020, Current protocols in microbiology.

[48]  Malik Peiris,et al.  Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia , 2020, Clinical chemistry.

[49]  H. Feldmann,et al.  Defining the Syrian hamster as a highly susceptible preclinical model for SARS-CoV-2 infection , 2020, Emerging microbes & infections.

[50]  Kimberly J. Hassett,et al.  Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines , 2019, Molecular therapy. Nucleic acids.